A Study of AK0529 in Chinese Infants Hospitalized With RSV

  • STATUS
    Not Recruiting
  • days left to enroll
    4
  • participants needed
    249
  • sponsor
    Ark Biosciences Inc.
Updated on 18 April 2022

Summary

This is a randomized, double-blind, placebo-controlled, multicenter, phase III study to be conducted in infants hospitalized with RSV infection in China. The main objectives of this study are to investigate the efficacy and safety of AK0529 in Chinese infants.

Details
Condition Respiratory syncytial virus infection, rsv infection
Treatment AK0529, Matching placebo of AK0529
Clinical Study IdentifierNCT04231968
SponsorArk Biosciences Inc.
Last Modified on18 April 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note